Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Pituitary Neoplasms 7Neuroendocrine Tumors 6Carcinoid Tumor 5Acromegaly 5Prostatic Neoplasms 4Pancreatic Neoplasms 4Gastro-enteropancreatic neuroendocrine tumor 3Pituitary ACTH Hypersecretion 2Neoplasms 2Neoplasm Metastasis 2Nelson Syndrome 2Multiple Myeloma 2Liver Neoplasms 2Growth Disorders 2Gigantism 2Carcinoma, Intraductal, Noninfiltrating 2Carcinoma, Hepatocellular 2ACTH Syndrome, Ectopic 2Uveal Melanoma 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Serotonin Syndrome 1Sarcoma, Synovial 1Prolactinoma 1Prolactin-Producing Pituitary Tumor 1Primary Inoperable Thymoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peritoneal Neoplasms 1Pancreatic Fistula 1Neuroectodermal Tumors, Primitive 1

Interventions

Tamoxifen 25Radiotherapy 15Chemotherapy, Adjuvant 11Anastrozole 11Specimen Handling 10Neoadjuvant Therapy 8Letrozole 8Biopsy 7Radiation 6Mastectomy, Segmental 6Magnetic Resonance Spectroscopy 6Immunohistochemistry 5Gene Expression Profiling 5exemestane 4Surgical Procedures, Operative 4Sentinel Lymph Node Biopsy 4Radiotherapy, Intensity-Modulated 4Radiotherapy, Conformal 4Psychiatric Rehabilitation 4Mass Spectrometry 4Early Intervention, Educational 4Counseling 4afimoxifene 3Trastuzumab 3Surveys and Questionnaires 3Reverse Transcriptase Polymerase Chain Reaction 3Radiation Dose Hypofractionation 3Methods 3Mastectomy 3High-Energy Shock Waves 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Intraductal, Noninfiltrating × pasireotide × Clear all
NCT01372618 2017-12-27

Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor

NYU Langone Health

Phase 1/2 Terminated
9 enrolled 3 charts
Breast

Carcinoma, Intraductal, Noninfiltrating

NCT01372644 2016-12-05

Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial

NYU Langone Health

Phase 1 Completed
15 enrolled
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡